|4.||Giant Lymph Node Hyperplasia (Castleman's Disease)
|5.||Systemic Lupus Erythematosus (Libman-Sacks Disease)
|1.||Martini, Alberto: 47 articles (01/2016 - 10/2002)|
|2.||Ruperto, N: 37 articles (01/2010 - 07/2001)|
|3.||Yokota, Shumpei: 34 articles (04/2015 - 09/2003)|
|4.||Paediatric Rheumatology International Trials Organisation: 32 articles (09/2007 - 07/2001)|
|5.||Wulffraat, Nico M: 29 articles (12/2015 - 02/2003)|
|6.||Ruperto, Nicolino: 26 articles (01/2016 - 07/2004)|
|7.||Mori, Masaaki: 26 articles (01/2015 - 01/2004)|
|8.||Horneff, Gerd: 25 articles (12/2015 - 04/2004)|
|9.||Imagawa, Tomoyuki: 25 articles (06/2014 - 01/2004)|
|10.||Wedderburn, Lucy R: 24 articles (12/2015 - 01/2006)|
|1.||TNFR-Fc fusion protein (etanercept)FDA Link
01/01/2011 - "Complete control of disease activity and remission induced by treatment with etanercept in juvenile idiopathic arthritis."
08/01/2009 - "Treatment with etanercept once weekly using a double dosage leads to a significant improvement of disease activity in patients with active polyarticular course juvenile idiopathic arthritis and is well tolerated."
01/01/2003 - "In patients with polyarticular-course juvenile rheumatoid arthritis, etanercept resulted in improvements in all measures of disease activity and was significantly more effective than placebo at reducing disease flare. "
01/01/2002 - "In patients with polyarticular-course juvenile rheumatoid arthritis, etanercept resulted in improvements in all measures of disease activity and was significantly more effective than placebo at reducing disease flare. "
07/01/2001 - "To evaluate safety and efficacy of high dose etanercept (> 0.8 mg/kg, maximum 25 mg subcutaneously twice weekly) (Enbrel) in children with juvenile rheumatoid arthritis (JRA) and inadequate prior response to standard dose etanercept. "
|2.||Methotrexate (Mexate)FDA LinkGeneric
01/01/2015 - "Children and young people (CYP) with juvenile idiopathic arthritis (JIA) are known to have impaired health-related quality of life (HRQoL), which is improved significantly for many by treatment with methotrexate (MTX). "
04/01/2009 - "An improved high-performance liquid chromatography method for quantification of methotrexate polyglutamates in red blood cells of children with juvenile idiopathic arthritis."
07/01/2000 - "The results demonstrated the following: (1) radiographic evidence of condylar degeneration was apparent in 63% of all patients with juvenile rheumatoid arthritis with pauciarticular patients showing less temporomandibular involvement than polyarticular patients; (2) polyarticular juvenile rheumatoid arthritis patients receiving methotrexate showed less severe temporomandibular joint involvement than the polyarticular patients not receiving methotrexate; (3) the craniofacial structure was affected to a greater extent in the polyarticular form of the disease; (4) the craniomandibular index scores were significantly greater in the polyarticular group; (5) vertical height asymmetry and chin deviation were noted in more than 50% of the patients; and (6) there was a correlation between the severity of condylar lesions and cephalometric findings (ie, mandibular retroposition, posterior rotation, smaller ramus and mandibular dimensions) and the onset and duration of the disease. "
07/01/2004 - "To compare the safety and efficacy of parenteral methotrexate (MTX) at an intermediate dosage (15 mg/m(2)/week) versus a higher dosage (30 mg/m(2)/week) in patients with polyarticular-course juvenile idiopathic arthritis (JIA) who failed to improve while receiving standard dosages of MTX (8-12.5 mg/m(2)/week). "
07/01/2000 - "In conclusion, under the conditions of this study, methotrexate therapy was effective in minimizing temporomandibular joint destruction and craniofacial dysmorphology in juvenile rheumatoid arthritis patients with the polyarticular form of the disease."
01/01/2015 - "Successful treatment with tocilizumab every 4 weeks of a low disease activity group who achieve a drug-free remission in patients with systemic-onset juvenile idiopathic arthritis."
06/01/2014 - "Tocilizumab (TCZ), an antiinterleukin-6 receptor monoclonal antibody, is clinically beneficial in patients with systemic-onset juvenile idiopathic arthritis (sJIA). "
03/22/2008 - "Tocilizumab is effective in children with systemic-onset juvenile idiopathic arthritis. "
07/01/2014 - "The safety and efficacy of tocilizumab (TCZ), an anti-IL-6 receptor monoclonal antibody, have been reported in the treatment of children with systemic juvenile idiopathic arthritis (sJIA). "
02/01/2012 - "We evaluated the safety and efficacy of tocilizumab in polyarticular-course juvenile idiopathic arthritis (pJIA) with polyarticular or oligoarticular onset. "
|4.||Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA
05/01/2009 - "To assess the frequency of clinical remission in a cohort of patients with systemic juvenile idiopathic arthritis (JIA) who received continuous anti-tumor necrosis factor (TNF) therapy; and to identify potential predictors of remission. "
10/01/2011 - "To estimate the length of time to disease flare and the likelihood of achieving clinical remission after discontinuation of treatment with tumor necrosis factor α (TNFα) blockers in patients with juvenile idiopathic arthritis (JIA). "
05/01/2009 - "Clinical remission in patients with systemic juvenile idiopathic arthritis treated with anti-tumor necrosis factor agents."
01/01/2014 - "The study is aimed to evaluate body composition and bone status in adolescent and adult patients with active juvenile idiopathic arthritis (JIA) untreated with tumor necrosis factor alpha inhibitors. "
08/01/2012 - "The aim of this study was to determine whether the tumor necrosis factor (TNF) promoter polymorphisms confer susceptibility to juvenile idiopathic arthritis (JIA). "
|5.||Interleukin-6 (Interleukin 6)IBA
03/01/2005 - "Targeting the interleukin-6 receptor: a new treatment for systemic juvenile idiopathic arthritis?"
01/01/2016 - "IL-6 blockers in systemic onset juvenile idiopathic arthritis."
11/01/2015 - "Systemic juvenile idiopathic arthritis (JIA) is associated with high levels of interleukin-6 (IL-6) in the serum and synovial fluid, and impairment of natural killer (NK) cell function is often observed. "
02/01/2014 - "The p38-mediated rapid down-regulation of cell surface gp130 expression impairs interleukin-6 signaling in the synovial fluid of juvenile idiopathic arthritis patients."
11/01/2008 - "Growth velocity and interleukin 6 concentrations in juvenile idiopathic arthritis."
|6.||Interleukin 1 Receptor Antagonist Protein (Anakinra)FDA Link
11/01/2012 - "Anakinra: a safe and effective first-line treatment in systemic onset juvenile idiopathic arthritis (SoJIA)."
08/01/2015 - "To assess anakinra as a therapy for systemic juvenile idiopathic arthritis (sJIA) in a single-center series. "
08/01/2015 - "Anakinra in Systemic Juvenile Idiopathic Arthritis: A Single-center Experience."
01/01/2013 - "Anakinra pharmacokinetics and pharmacodynamics were investigated in children and adolescents treated for systemic-onset juvenile idiopathic arthritis (SJIA) and autoinflammatory syndromes. "
01/01/2013 - "Anakinra pharmacokinetics in children and adolescents with systemic-onset juvenile idiopathic arthritis and autoinflammatory syndromes."
|7.||adalimumab (Humira)FDA Link
03/01/2011 - "To evaluate the safety and efficacy of adalimumab (AD) administration in patients with juvenile idiopathic arthritis (JIA). "
03/01/2011 - "Safety and efficacy of adalimumab treatment in Greek children with juvenile idiopathic arthritis."
01/01/2014 - "The objective of this study was to assess the safety of adalimumab in patients aged 2 to <4 years old or ≥4 years old weighing <15 kg with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA). "
12/01/2012 - "The objective of this study was to evaluate the efficacy, pharmacokinetics, and safety of adalimumab in patients with polyarticular juvenile idiopathic arthritis (JIA) in Japan. "
07/01/2015 - "We describe a case of cutaneous LE in a 16-year-old girl treated with adalimumab for juvenile idiopathic arthritis. "
|8.||infliximab (Remicade)FDA Link
09/01/2007 - "To evaluate the safety and efficacy of infliximab in the treatment of juvenile rheumatoid arthritis (JRA). "
09/01/2008 - "The results of a pivotal trial of infliximab in polyarticular juvenile idiopathic arthritis suggested efficacy, but the primary outcome was not significantly different from placebo. "
07/01/2015 - "60% were female, ∼half had juvenile idiopathic arthritis, and most were treated with infliximab. "
10/01/2013 - "To review our experiences with high-dose infliximab (IFX) to treat juvenile idiopathic arthritis (JIA). "
10/01/2013 - "High doses of infliximab in the management of juvenile idiopathic arthritis."
|9.||Interleukin-1 (Interleukin 1)IBA
04/01/2014 - "Effectiveness of first-line treatment with recombinant interleukin-1 receptor antagonist in steroid-naive patients with new-onset systemic juvenile idiopathic arthritis: results of a prospective cohort study."
03/01/2012 - "Renal and systemic-onset juvenile idiopathic arthritis remission occurred in one patient under anti-interleukin 1 (anti-IL-1) treatment associated with immunosuppressive drugs. "
06/01/2008 - "Comprehensive association study of genetic variants in the IL-1 gene family in systemic juvenile idiopathic arthritis."
12/01/2015 - "Auto-inflammatory diseases and systemic onset juvenile idiopathic arthritis (JIA) are examples of chronic inflammatory diseases that are IL-1 dependent. "
09/01/2014 - "Interleukin-1 blockade has been utilized to treat systemic onset juvenile idiopathic arthritis and related autoinflammatory diseases. "
02/01/2009 - "MRI in juvenile idiopathic arthritis and juvenile dermatomyositis."
07/01/1998 - "Children with juvenile chronic arthritis comprised 28.8% and juvenile dermatomyositis 10%. "
08/01/1997 - "New-onset juvenile dermatomyositis: comparisons with a healthy cohort and children with juvenile rheumatoid arthritis."
01/01/2013 - "To date, core sets of response variables are defined for juvenile idiopathic arthritis, juvenile systemic lupus erythematosus, and juvenile dermatomyositis, as well as definitions for improvement in response to therapy. "
08/01/2008 - "The PRINTO and PRCSG networks have standardized the evaluation of response to therapy in juvenile idiopathic arthritis (JIA), juvenile systemic lupus erythematosus, and juvenile dermatomyositis, drafted clinical remission criteria in JIA, and provided cross-cultural adapted and validated quality of life instruments including the Childhood Health Assessment Questionnaire and the Child Health Questionnaire into 32 different languages. "
12/01/2012 - "Intra-articular corticosteroid injections are a safe and effective treatment for patients with juvenile idiopathic arthritis. "
08/01/2012 - "The purpose of this study was to evaluate the safety and efficacy of intra-articular corticosteroid injections (IACIs) of the temporomandibular joint (TMJ) in children with juvenile idiopathic arthritis (JIA) when administered by an oral and maxillofacial surgeon without imaging guidance. "
04/01/2008 - "Factors influencing the efficacy of intra-articular steroid injections in patients with juvenile idiopathic arthritis."
05/01/2014 - "This study aimed to evaluate the efficacy and safety of intra-articular glucocorticoid (IAG) injections in our institution in children with juvenile idiopathic arthritis (JIA). "
01/01/2011 - "To study the systemic effects of intra-articular (IA) glucocorticoid (GC) injections in juvenile idiopathic arthritis (JIA). "
07/01/2005 - "The purpose of this study was to evaluate the outcome of total knee arthroplasty in patients with juvenile rheumatoid arthritis who had been followed for a minimum of twelve years. "
12/01/2002 - "Because controversy surrounds the management of end-stage hip disease in juvenile rheumatoid arthritis (JRA), this study evaluated the long-term outcome of bipolar hemiarthroplasty as an alternative to conventional joint arthroplasty. "
03/01/2015 - "Juvenile Idiopathic Arthritis (JIA) is a common rheumatologic disease that frequently involves the hip joint and requires treatment with total hip arthroplasty (THA). "
03/01/2015 - "Implant survival and patient-reported outcomes after total hip arthroplasty in young patients with juvenile idiopathic arthritis."
02/01/2014 - "Revision total hip arthroplasty (THA) in patients with juvenile idiopathic arthritis (JIA) is challenging as a result of the patient's young age, systemic disease, multiple affected joints, small proportions, and bone loss. "
07/01/2015 - "The introduction of biological therapies opened a new era of treatment of juvenile idiopathic arthritis. "
07/01/2015 - "Safety of biologic therapies for the treatment of juvenile idiopathic arthritis."
12/01/2014 - "Biologic therapies are considered the standard of care for children with the most severe forms of juvenile idiopathic arthritis (JIA). "
05/01/2013 - "Long-term safety of biologic therapy of juvenile idiopathic arthritis]."
02/01/2013 - "Paediatric rheumatology: Biologic therapy for systemic juvenile idiopathic arthritis--times they are a'changing!"
|4.||Drug Therapy (Chemotherapy)
09/01/2011 - "In juvenile idiopathic arthritis (JIA), the efficacy of very early disease-modifying drug therapy, synthetic or biological, is not well known. "
01/01/2012 - "A commentary on TREAT: the trial of early aggressive drug therapy in juvenile idiopathic arthritis."
12/01/1987 - "To determine the prevalence of coagulopathy in juvenile rheumatoid arthritis, results of repeated coagulation studies obtained on 73 patients over one year were correlated with disease activity, liver function abnormalities and drug therapy. "
06/01/2013 - "To determine the spectrum of clinical presentation, laboratory parameters and drug therapy in patients with Juvenile Rheumatoid Arthritis (JRA). "
06/01/2013 - "Juvenile idiopathic arthritis: an update on current pharmacotherapy and future perspectives."
|5.||Stem Cell Transplantation
02/01/2014 - "Autologous stem cell transplantation (ASCT) induces long-term drug-free disease remission in patients with juvenile idiopathic arthritis. "
10/01/2004 - "To evaluate the safety and efficacy of autologous stem cell transplantation (ASCT) for refractory juvenile idiopathic arthritis (JIA). "
11/01/2009 - "As part of collaborative multi-centre study started in 2000, 7 children in the UK fulfilled the inclusion criteria for treatment with autologous T cell depleted (TCD) haematopoietic stem cell transplantation (HSCT) for severe juvenile idiopathic arthritis (JIA). "
11/01/2009 - "Autologous T cell depleted haematopoietic stem cell transplantation in children with severe juvenile idiopathic arthritis in the UK (2000-2007)."
12/01/2008 - "Current perspectives of autologous stem cell transplantation for severe Juvenile Idiopathic Arthritis."